Sirnaomics Completes Phase I Trial of STP707 for Advanced Solid Tumors

Sirnaomics Ltd. announced that its wholly-owned subsidiary, Sirnaomics, Inc., has completed Phase I clinical trials for its investigational drug STP707. The company has formally submitted the Clinical Study Report (CSR) to the U.S. Food and Drug Administration (FDA). The Phase I study involved adult patients with advanced, metastatic, or inoperable solid tumors who had not responded to standard treatments. STP707 was administered intravenously at various doses and demonstrated manageable side effects, with some patients achieving stable disease. The company indicated that completion of Phase I and submission of the CSR represent a significant milestone, and it is preparing to discuss the Phase II development strategy with the FDA. The results from Phase I have already been submitted and presented to the regulatory authority. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sirnaomics Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251222-11963405), on December 22, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)